Paul Friedman, Madrigal Pharmaceuticals CEO
Madrigal’s NASH drug wins on pivotal PhIII endpoints, setting stage for accelerated approval
Madrigal Pharmaceuticals says its NASH drug, resmetirom, has met its early endpoints in a Phase III trial, marking a major success in a field littered …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
